Telangiectasis
Conditions
Keywords
Telangiectasias, Leakage, Bevacizumab, Telangiectasias secondary to Branch Retinal Vein Occlusion (BRVO), Idiopathic juxtafoveal retinal telangiectasias
Brief summary
Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias
Detailed description
After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS Best Corrected visual acuity (BCVA), fluorescein angiogram (FA) and Optical Coherence Tomography (OCT)findings. We found an improvement in visual acuity and reduction of FA leakage and decrease retinal thickness in OCT.
Interventions
DRUGBevacizumab
Sponsors
Asociación para Evitar la Ceguera en México
Study design
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Inclusion criteria
* Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion * Patients with Idiopathic Juxtafoveal Retinal Telangiectasias
Exclusion criteria
* Diabetic Retinopathy and Diabetic Macular Edema * Hypertensive Retinopathy * Choroidal Neovascularization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected Visual Acuity | — |
| Fluorescein Angiogram: Leakage | — |
| Optical Coherence Tomography: Retinal thickness | — |
Countries
Mexico
Outcome results
None listed